 NEW YORK, NY ACCESSWIRE March 4, 2021 Kadmon Holdings, Inc. NASDAQ:KDMN today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2020. With the acceptance of Kadmons new drug application for belumosudil in cGVHD in hand, we are preparing for our potential commercial launch in light of our May 30th PDUFA date, said Harlan W. 